(Q37055372)

18 August 2017

1 reference

title

New frontiers in nanotechnology for cancer treatment (English)

1 reference

18 August 2017

0 references

3

Jerome P Richie

1 reference

18 August 2017

Robert S. Langer, Jr.

5

object named as

Robert Langer

1 reference

18 August 2017

Frank Alexis

1

1 reference

18 August 2017

June-Wha Rhee

2

1 reference

18 August 2017

Aleksandar F Radovic-Moreno

4

1 reference

18 August 2017

Omid C Farokhzad

6

1 reference

18 August 2017

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

26

1 reference

18 August 2017

1

1 reference

18 August 2017

74-85

1 reference

Cancer nanotechnology: opportunities and challenges

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Nanomedicine: developing smarter therapeutic and diagnostic modalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

The 'right' size in nanobiotechnology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Small-scale systems for in vivo drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Nanoparticle-aptamer bioconjugates for cancer targeting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Recent advances with liposomes as pharmaceutical carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Diffusion of univalent ions across the lamellae of swollen phospholipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Delivery of molecular and cellular medicine to solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Ophthalmic drug delivery systems--recent advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Responsive polymeric delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers that respond sharply to temperature and pH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Characterization of glucose-mediated insulin release from implantable polymers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Biodegradable long-circulating polymeric nanospheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Stealth PLA-PEG nanoparticles as protein carriers for nasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Designing materials for biology and medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Polymers for the sustained release of proteins and other macromolecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

New methods of drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Drug delivery. Drugs on target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Advances in biomaterials, drug delivery, and bionanotechnology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Cell-specific targeting of nanoparticles by multivalent attachment of small molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

A theoretical model for the margination of particles within blood vessels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Targeting cancer cells with dendrimers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Dendrimers and dendritic polymers in drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Designing dendrimers for biological applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Dendrimers: novel polymeric nanoarchitectures for solubility enhancement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Polymer architecture and drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Trends and developments in liposome drug delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

RNA interference and human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Antisense approaches in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

In vitro selection of functional nucleic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Controlled assembly of dendrimer-like DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

New approaches to antibody therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Human antibodies from transgenic animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Selection of tumor-binding ligands in cancer patients with phage display libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Antibody targeted drugs as cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Mylotarg: antibody-targeted chemotherapy comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Targeted therapy of cancer: new prospects for antibodies and immunoconjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Searching for Peptide Ligands with an Epitope Library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Is phage display technology on target for developing peptide-based cancer drugs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Alpha v integrins as receptors for tumor targeting by circulating ligands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

A peptide isolated by phage display binds to ICAM-1 and inhibits binding to LFA-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Targeting tumor angiogenic vasculature using polymer-RGD conjugates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Efficient cancer therapy with a nanobody-based conjugate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Folate-mediated drug delivery: effect of alternative conjugation chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Receptor-mediated folate accumulation is regulated by the cellular folate content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Targeted and sustained drug delivery using PEGylated galactosylated liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Aptamers: an emerging class of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Methods developed for SELEX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Adaptive recognition by nucleic acid aptamers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Isolation and characterization of fluorophore-binding RNA aptamers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Detection of oncoprotein platelet-derived growth factor using a fluorescent signaling complex of an aptamer and TOTO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Aptamers evolved from live cells as effective molecular probes for cancer study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Aptamer:toxin conjugates that specifically target prostate tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.017

10.1016/J.UROLONC.2007.03.017

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference